摘要
细胞遗传学异常是多发性骨髓瘤(multiple myeloma,MM)患者危险分层重要依据。已证实1q21扩增是最常见的MM遗传学异常之一,多数研究表明1q21扩增影响MM患者预后。研究发现硼替佐米、沙利度胺及自体移植单独应用均不能消除1q21扩增引起的不良预后,但以硼替佐米为基础联合诱导、序贯自体造血干细胞移植巩固治疗或硼替佐米、来那度胺联合应用,有可能改善该高危细胞遗传学异常患者的预后。
Cytogenetic abnormality is an important basis for risk stratification of multiple myeloma(MM)patients.Chromosome 1 q21 amplification has been confirmed as one of the most common genetic abnormalities of MM,and most studies have shown that 1 q21 amplification affects the prognosis of MM patients.It was found that bortezomib,thalidomide and autologous transplantation alone could not eliminate the adverse prognosis caused by1 q21 amplification.However,bortezomib combined with autologous hematopoietic stem cell transplantation or combined application of bortezomib and lenalidomide may improve the prognosis of patients with high-risk cytogenetic abnormalities.
作者
刘颖
陈建斌
LIU Ying;CHEN Jian-bin(Department of Hematology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2019年第11期1343-1347,共5页
Chinese Journal of New Drugs
关键词
多发性骨髓瘤
硼替佐米
沙利度胺
来那度胺
自体造血干细胞移植
multiple myeloma
bortezomib
thalidomide
lenalidomide
autologous hematopoietic stem cell transplantation
